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Abstract
Background: Disorders of sex development (DSD) are congenital conditions in which chromosomal, gonadal, or
phenotypic sex is atypical. Clinical management of DSD is often difficult and currently only 13% of patients receive
an accurate clinical genetic diagnosis. To address this we have developed a massively parallel sequencing targeted
DSD gene panel which allows us to sequence all 64 known diagnostic DSD genes and candidate genes
simultaneously.
Results: We analyzed DNA from the largest reported international cohort of patients with DSD (278 patients
with 46,XY DSD and 48 with 46,XX DSD). Our targeted gene panel compares favorably with other sequencing
platforms. We found a total of 28 diagnostic genes that are implicated in DSD, highlighting the genetic spectrum of
this disorder. Sequencing revealed 93 previously unreported DSD gene variants. Overall, we identified a likely genetic
diagnosis in 43% of patients with 46,XY DSD. In patients with 46,XY disorders of androgen synthesis and action the
genetic diagnosis rate reached 60%. Surprisingly, little difference in diagnostic rate was observed between
singletons and trios. In many cases our findings are informative as to the likely cause of the DSD, which will
facilitate clinical management.
(Continued on next page)
* Correspondence: andrew.sinclair@mcri.edu.au
†Equal contributors
1Murdoch Childrens Research Institute, Melbourne, VIC, Australia
2Department of Paediatrics, University of Melbourne, Melbourne, VIC,
Australia
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Eggers et al. Genome Biology  (2016) 17:243 
DOI 10.1186/s13059-016-1105-y
(Continued from previous page)
Conclusions: Our massively parallel sequencing targeted DSD gene panel represents an economical means of
improving the genetic diagnostic capability for patients affected by DSD. Implementation of this panel in a large
cohort of patients has expanded our understanding of the underlying genetic etiology of DSD. The inclusion of
research candidate genes also provides an invaluable resource for future identification of novel genes.
Keywords: Disorders of sex development, Gonad, Testis, Ovaries, Ovotestes, Massively parallel sequencing, MPS,
Cohort, Targeted gene panel, Genetic diagnosis, Variant, Mutation
Background
Disorders of sex development (DSD) are defined as con-
genital conditions in which the chromosomal, gonadal,
or phenotypic sex is atypical [1]. This group of disorders
are highly heterogeneous and include clinical phenotypes
such as hypospadias (misplacement of the urethral me-
atus; 1 in 250 boys), ambiguous genitalia (1 in 4500 live
births), and complete XX or XY sex reversal (1 in 20,000
births) [2–4] (reviewed in [5]). DSD represent a major
pediatric concern and a significant healthcare burden
due to the difficult clinical management of these condi-
tions and, in some, the association with gonadal cancer
and infertility. Uncertainty about a child’s gender can be
extremely traumatic for the individual, parents, and
other family members and may carry profound psycho-
logical and reproductive consequences for the patient.
Most often the underlying cause of DSD is a variant
in a gene or genes regulating gonadal/genital or ste-
roidogenic pathways.
Providing a molecular diagnosis for patients with a
DSD and families can serve multiple purposes: naming
the underlying cause contributes to acceptance, reduces
stigma or blame, and provides crucial clues and guidance
for clinical management, including information on the
malignancy risks associated with some types of DSD [6].
A diagnosis is integral to genetic counseling and family
planning and yet it has been found that as few as 13% of
patients with a DSD will receive a clinical molecular
genetic diagnosis in the current hospital system [7].
Massively parallel sequencing (MPS) has been widely
adopted for the diagnosis of genetic diseases, especially
for monogenic congenital disorders, as it promises to
improve diagnosis and alter patient management through
rapid sequencing of many genes simultaneously at a lower
cost compared with sequential testing of multiple genes.
The process of deploying these genomic assays involves
extensive evaluation of technology, bioinformatics, and
clinical concerns to choose the right configuration for a
given setting. As technology advances and whole genome
sequencing (WGS) or whole exome sequencing (WES)
becomes more accessible, the choice of platform must
take both performance and cost into consideration. In
some countries either government or private health insur-
ance funding covers or contributes to the cost of WES to
diagnose DSD patients, and this has been reported for a
number of individuals affected by 46,XY DSD [8]. In
Australia, however, MPS is not yet covered by the national
Medicare system or private health insurance bodies. In
this environment, an MPS targeted gene panel offers
many advantages, such as relatively low cost, shorter turn-
around time, and smaller overheads in data handling and
analysis compared to WES or WGS. Indeed, numerous
gene panels have been successfully employed in the gen-
etic diagnosis of a variety of monogenic disorders [9], in-
cluding small cohorts of patients with 46,XY DSD [7, 10].
Finally, no studies have reported the usefulness of MPS
for patients with 46,XX DSD, nor have any large-scale
studies looked at the contribution of known DSD genes to
this heterogeneous condition.
Here, we report the application of an MPS targeted gene
panel to a cohort of patients affected by DSD (both 46,XX
and 46,XY DSD). This panel contains genes of both clin-
ical and research relevance that are associated with
gonadal or genital development as well as steroidogenic
pathways. It includes the majority of known diagnostic
genes for DSD, allowing us to perform the same diagnos-
tic test on all DSD patients and their participating family
members irrespective of their DSD phenotype. Perform-
ance evaluation of our MPS targeted DSD gene panel in
comparison to both WGS and well-characterized refer-
ence samples shows that it offers high sensitivity and spe-
cificity. The results from targeted genetic testing of 326
patients with DSD (and 129 of their family members) from
a wide spectrum of clinical presentations (the largest
known such cohort) are presented.
Results
A targeted DSD gene panel: performance evaluation
We designed a targeted gene panel for DSD using
HaloPlex (Agilent) technology. This system allowed us
to simultaneously sequence 64 known diagnostic genes
for DSD and an additional 967 candidate genes.
HaloPlex technology uses custom molecular inversion
probes (SureDesign software, Agilent) that are then used
for selective circularization-based target enrichment.
The known diagnostic genes have been compiled from
current knowledge of DSD sourced from PubMed and
clinical variant databases (such as HGMD and ClinVar)
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(Table 1). The candidate genes included in the panel
were selected from several sources, including research
studies reporting candidate DSD genes, genes implicated
in gonadal development from animal models, RNA-seq
studies, and known molecular pathways (such as Hedge-
hog signaling, WNT signaling, and androgen receptor
(AR) interacting proteins). In addition we have in-
cluded relevant regulatory regions and microRNAs,
which are not possible to detect using WES. This
manuscript reports only variants found in the 64
diagnostic DSD genes; however, ongoing work in our
research group is addressing the contribution of can-
didate genes to DSD.
To provide a benchmark of assay quality, we created an
evaluation data set that included 16 samples, three of
which had been previously sequenced using WGS. These
16 samples were sequenced using our targeted gene panel
on a single run using an Illumina MiSeq instrument, con-
figured to produce 2 × 150-bp paired-end reads.
This dataset was evaluated to ascertain performance of
the panel with respect to several standard benchmarks
for MPS assays, including coverage, targeting efficiency,
and variant calling accuracy.
Coverage
A commonly accepted threshold for variant calling is ap-
proximately 30× in research settings, while higher thresh-
olds are frequently sought for diagnostic use. In aggregate,
the targeted gene sequencing of our evaluation data set
yielded mean (median) coverage depths well in excess of
these thresholds, varying between 135× (115×) and 190×
(161×). However, the coverage depth was highly variable
across different genomic regions. Approximately 10% of
bases were covered at lower than 30× and the upper 10%
of bases were covered at greater than 280× (Fig. 1a). WGS
showed more even coverage, with 90% of bases having at
least half of the mean coverage compared with only 70%
of bases having half the mean coverage for our targeted
panel (Fig. 1b). Nonetheless, coverage uniformity of our
targeted gene panel (HaloPlex) is approximately similar to
that cited when comparing other targeted capture tech-
nologies, including WES [11].
Targeting efficiency
Averaged across the evaluation samples, we observed that
92% of sequenced fragments overlapped the target region
by at least 1 bp. This percentage compares favorably with
commonly cited targeting accuracy for competing plat-
forms such as Agilent SureSelect and Nimblegen [12].
However, we also observe that a substantial proportion of
the reads overlap the targeted regions by only a small
amount. If targeting efficiency is calculated at the base
level, only 66% of sequenced bases overlapped the targeted
regions, significantly reducing the overall efficiency.
Adapter contamination
We found that a high fraction of reads experienced “read
through” into adapters, resulting in numerous high con-
fidence false positive variant detections when analysis
was run using raw data. A satisfactory compromise be-
tween over-trimming (trimming of non-adapter sequence)
and under-trimming (substantial adapter contamination
remaining in the data) was not achieved using a num-
ber of tools, including Trimmomatic [13], SeqPrep
(https://github.com/jstjohn/SeqPrep) and Agilent’s MPS
ReadTrimmer (http://download.chem.agilent.com/software
/ngs_readtrimmer). Thus, a custom trimming program was
designed, resulting in nearly 100% of reads being correctly
trimmed of adapter sequences (see “Methods”).
Underperforming amplicons
Performance of our targeted gene panel at any given
genomic locus is critically dependent on the perform-
ance of the handful of amplicons that span the locus.
The 29,928 amplicons in our evaluation design showed
highly variable performance, including a substantial
number of amplicons (8% on average) to which no reads
are mapped. Some of these “failures” occurred consist-
ently between samples: 38% of amplicons that failed did
so in all of our evaluation samples. However, we also
observed that 13% of failures occurred sporadically, in
only a single sample.
Variant calling accuracy
We evaluated variant calling accuracy using two inde-
pendent data sets: firstly, the three samples sequenced
independently using WGS offer a comparison to a tech-
nology free of bias due to the targeted capture process.
Secondly, we sequenced a trio (NA12877, NA12878,
NA12879) of samples from the 1000 Genomes CEPH
pedigree. These samples have been intensively studied
and sets of gold standard variant calls are available for
comparison from the Illumina Platinum Genomes Project
(http://www.illumina.com/platinumgenomes/). In com-
parison to the gold standard reference call set, we ob-
served high sensitivity and specificity of our targeted gene
panel. At a false positive rate of 2%, variant calls for
NA12878 and NA12877 achieved an overall sensitivity of
97% (for 974 variant calls) and 95% (for 1278 variants
calls), respectively. Variant calls were compared using the
RTG vcfeval (http://realtimegenomics.com/products/rtg-
tools/Cleary2015) utility for single nucleotide changes and
INDELs smaller than 10 bp (Fig. 1c). In the case of our
samples that were also sequenced using WGS, we manu-
ally scrutinized differences between variant calls obtained
from our targeted gene panel and WGS data to ascertain
the likely cause for each discrepancy. The predominant
reason for false negatives in our panel variant calls was
due to the amplicon design. That is, in 63% of cases either
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Table 1 Diagnostic DSD genes included in the panel
Gene Locus OMIM Associated DSD Inheritance Coverage (>20×)
Gonadal development
BMP15 Xp11.22 300247 46,XX DSD—ovarian dysgenesis AD 95%
CBX2 17q25.3 602770 46,XY DSD CGD AR 96%
DHH 12q13.12 605423 46XY PGD or CGD AR, AD 99%
DMRT1 9p24.3 602424 46,XY DSD AD: deletion 98%
DMRT2 9p24.3 604935 46,XY DSD AD: deletion 99%
FOXL2 3q22.3 608996 POI alone or with blepharophimosis, ptosis, and epicanthus
inversus syndrome
AD 94%
GATA4 8p23.1 600576 46,XY DSD AD 91%
NR0B1 Xp21.2 300473 46,XY GD—gain of function XL-dup 100%
46,XX CAH with HH XLR
NR5A1 9q33.3 184757 46,XY DSD (various) AD 100%
46,XX POI AD
MAP3K1 5q11.2 600982 46,XY GD AD 99%
RSPO1 1p34.3 609595 46,XX OT DSD with palmoplantar hyperkeratosis AR 94%
SOX3 Xq27.1 313430 46,XX T or OT DSD—gain of function XL: dup 92%
SOX9 17q24.3 608106 46,XY GD and campomelic dysplasia AD 95%
46,XX T DSD—duplication AD: dup
SRY Yp11.2 480000 46,XX T DSD—gain of function Translocation 58%*
46,XY ovarian DSD AD
TSPYL1 6q22.1 604714 46,XY DSD with sudden infant death syndrome AR 99%
WNT4 1p36.12 603490 46,XY ovo or OT DSD or 46,XY CGD—duplication AD: dup 99%
46,XX T DSD AR
46,XX MRKH AD
WT1 11p13 607102 Frasier syndrome and Denys-Drash AD 99%
ZFPM2 8q23.1 603693 46,XY GD AD 99%
Gonadal differentiation (androgen synthesis and action)
AKR1C2 10p15.1 600450 46,XY DSD AR 82%
AKR1C4 10p15.1 600451 46,XY DSD AR 99%
AMH 19p13.3 600957 PMDS AR 94%
AMHR2 12q13.13 600956 PMDS AR 100%
AR Xq12 313700 46,XY DSD. Complete AIS/partial AIS, isolated hypospadia XL 97%
ARX Xp21.3 300215 X-linked lissencephaly with ambiguous genitalia XL 90%
ATRX Xq21.1 300032 46,XY DSD associated with alpha-thalassemia X-linked intellectual
disability syndrome
XL 99%
CDKN1C 11p15.4 600856 Genital anomalies in association with Beckwith-Wiedemann and
IMAGE syndrome
AD 61%
CYB5A 18q22.3 613218 46,XY DSD AR 99%




CYP11B1 8q24.3 610613 46,XX DSD. CAH due to steroid 11-beta-hydroxylase deficiency AR 86%
CYP17A1 10q24.32 609300 46, XY DSD. 17,20-lyase deficiency CAH AR 100%
CYP19A1 15q21.2 107910 46, XY DSD. Aromatase deficiency AR 100%
CYP21A2 6p21.33 613815 46, XX DSD virilization—21-hydroxylase-deficient CAH AR 6%
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Table 1 Diagnostic DSD genes included in the panel (Continued)
FGFR2 10q26.13 176943 46,XY GD with craniosynotosis. Apert syndrome AD 99%
HSD17B3 9q22.32 605573 46,XY DSD—17-β-hydroxysteroid dehydrogenase III deficiency AR 100%
HSD17B4 5q23.1 233400 Perrault syndrome (with ovarian dygeneisis in 46,XX) AR 98%




LHCGR 2p16.3 152790 46,XY DSD—Leydig cell hypoplasia, AR 100%
Precocious puberty (male) AD
NR3C1 5q31.3 138040 46,XX hyperandrogenism AD 96%
POR 7q11.23 124015 Cytochrome P450 oxidoreductase deficiency AR 95%
SRD5A2 2p23.1 607306 46,XY DSD. Steroid 5-α-reductase deficiency AR 100%
Hypospadias AD
STAR 8p11.23 600617 46,XY DSD—cholesterol desmolase-defient CAH AR 100%
Central causes of hypogonadism
BBS9 7p14.3 615986 Bardet-Biedl syndrome AR 96%
CHD7 8q12.2 608892 CHH or KS. CHARGE syndrome AD 99%
FGF8 10q24.32 612702 CHH or KS AD 88%
FGFR1 8p11.23 147950 CHH or KS AD 100%
FSHB 11p14.1 136530 CHH AD 98%
FSHR 2p16.3 136435 46,XX ovarian dysgenesis AR 100%
GNRH1 8p21.2 152760 CHH AR 100%
GNRHR 4q13.2 138850 CHH AR 100%
HESX1 3p14.3 601802 KS or CPHD AD 98%
KAL1 Xp22.31 300836 CHH or KS XL 97%
KISS1R 19p13.3 604161 CHH or KS AD 96%
LEP 7q32.1 164160 CHH with obesity AR 99%
LHX3 9q34.3 600577 CPHD AR 89%
PROK2 3p13 607002 CHH or KS AD 99%
PROKR2 20p12.3 607123 CHH or KS AD 100%
PROP1 5q35.3 601538 CPHD AR 98%
TAC3 12q13.3 162330 CHH AR 98%
WDR11 10q26.12 606417 CHH or KS AD 93%
Other (isolated hypospadia, cryptorchidism, MRKH):
ATF3 1q32.3 603148 46,XY isolated hypospadias AD 97%
HOXA13 7p15.2 142959 Hand-foot uterus syndrome - MRKH in 46,XX AD 93%
Guttmacher syndrome in 46,XY including hypospadias AD
INSL3 19p13.11 146738 Cryptorchidism AD 99%
MAMLD1 Xq28 300120 Hypospadias XL 100%
RXFP2 13q13.1 606655 Cryptorchidism AD 96%
DSD genes considered as diagnostic that were included in the targeted gene panel. These are grouped according to their main action during development
(gonadal development, androgen or hormonal activity, central causes of hypogonadism or other). Gene locus is shown as well as reference number for OMIM
(Online Mendelian Inheritance in Man). The associated DSD(s) are shown for each gene. CGD complete gonadal dysgenesis, PGD partial gonadal dysgenesis, POI
premature ovarian insufficiency, GD gonadal dysgenesis, CAH congenital adrenal hyperplasia, HH hypogonadotrophic hypogonadism, OT ovo-testicular, T testicular,
MRKH Mayer-Rokitansky-Küster-Hauser syndrome, PMDS persistent Müllerian duct syndrome, AIS androgen insensitivity syndrome, CHH congenital hypogonadotrophic
hypogonadism, KS Kallmann syndrome, CPHD central pituitary hormone defect. Mode of inheritance is shown: AR autosomal recessive, AD autosomal dominant,
XL X-linked, dup duplication (gain of function). The percentage coverage with greater than 20× depth is also shown
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no amplicon was present over the region or the amplicons
produced insufficient coverage depth to call a variant. False
positives in our targeted gene panel data occurred due to
either systematic misalignment of a particular amplicon or
to regions of poor sequencing quality that generated large
numbers of sequencing errors. In both cases the errors
were systematically confined to narrow genomic loci and
thus could be eliminated bioinformatically.
A large international cohort of patients with DSDs
We have assembled DNA from the largest known inter-
national cohort of patients affected by DSD. A total of
326 patients with a DSD were included in this sequen-
cing analysis (Table 2). This included 251 patients se-
quenced as singletons and 75 patients with family
members (129 family members, duos/trios or siblings;
Table 2). We have classified the cohort of patients ac-
cording to the 2006 Consensus Statement on Manage-
ment of Intersex Disorders [1] (Table 2). Given the large
number of patients, detailed clinical notes are beyond
the scope of this meta-analysis and have only been pro-
vided where a patient is discussed in detail. It is import-
ant to note that persons with a known genetic etiology
for sex chromosome disorders, as well as those with
congenital adrenal hyperplasia (CAH), were not included
in this study.
Of the 326 patients, 278 were classified as having
46,XY DSD based on previous chromosomal karyotyping
and clinical presentation (Table 2). These include 24 pa-
tients with 46,XY complete gonadal dysgenesis (CGD),
21 with 46,XY partial gonadal dysgenesis (PGD), and six
with 46,XY ovotesticular DSD (OT). These patients have
been classified as having a disorder of gonadal (testicu-
lar) development (Table 2). Furthermore, we have 37
46,XY DSD patients with a suspected disorder in andro-
gen synthesis and action (DASA). Another 56 patients




Fig. 1 Coverage and variant properties of the panel and patient cohort.
a The cumulative distribution read coverage across the targeted regions
of the HaloPlex panel for 16 evaluation samples. The vertical axis shows
the percentage of bases covered with at least the level of coverage
specified by the horizontal axis. Although the median coverage is
acceptable for all samples, it is notable that 10% of bases are covered at
less than 25×, while another 10% of bases are covered at more than
280×. b Coverage depth uniformity of HaloPlex compared to whole
genome sequencing (WGS). The cumulative coverage distribution is
shown for three samples sequenced by both technologies. HaloPlex is
notably less uniform, having a flatter distribution than WGS. c Receiver-
operator characteristic (ROC) curve showing sensitivity versus false
positive rate (1− precision) for detecting single nucleotide variants and
INDELs smaller than 10 bp, compared to high confidence calls for
samples NA12878 and NA12877. Call sets were obtained from
the Illumina Platinum Genomes project. A sensitivity of 97 and
95%, respectively, is achieved for a false positive rate smaller
than approximately 2% in both cases
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Table 2 Disorder of sex development patient cohort and variant summary








Pathogenic Likely pathogenic VUS
46,XY DSD
(A) Disorders of gonadal (testicular) development
46,XY Complete gonadal dysgenesis (CGD) 3 21 24 11 13 6 7 0
46,XY Partial gonadal dysgenesis (PGD) 2 19 21 13 8 2 4 2
46,XY Ovo-testicular DSD (OT) 3 3 6 4 2 1 1 0
46,XY Gonadal regression (GR) 0 1 1 1 0 0 0 0
52 29 23 Genetic diagnosis = 21 (40%)
(B) Disorders in androgen synthesis or action
46,XY Suspected androgen syn/action
disorder (DASA)
12 23 35 11 24 18 2 4
46,XY Leydig cell hypoplasia (LCH) 0 1 1 0 1 0 1 0
46,XY Persistent mullerian duct
syndrome (PMDS)
1 0 1 0 1 1 0 0
37 11 26 Genetic diagnosis = 22 (60%)
(C) Other
46,XY Hypospadias 12 34 46 20 26 6 10 10
46,XY Syndromic 5 4 9 6 3 1 1 1
46,XY Diphallus 0 1 1 1 0 0 0 0
56 27 29 Genetic diagnosis = 18 (32%)
(D) Unknown
46,XY DSD (origin unknown) 25 108 133 52 81 41 16 24
Genetic diagnosis = 57 (43%)
Total 46,XY DSD 63 215 278 119 159 76 42 41
Genetic diagnosis = 118 (43%)
46,XX DSD
(A) Disorders of gonadal (ovarian) development
46,XX Testicular DSD 2 14 16 8 8 8 0 0
46,XX Ovotesticular DSD 2 5 7 6 1 0 0 1
46,XX Gonadal dysgenesis (GD) 2 1 3 3 0 0 0 0
26 17 9 Genetic diagnosis = 8 (31%)
(B) Androgen excess 0
(C) Other
46,XX MRKH 0 9 9 9 0 0 0 0
46,XX Dysplastic ovaries 1 0 1 1 0 0 0 0
46,XX Syndromic 1 1 2 2 0 0 0 0
12 12 0
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including 46 with hypospadias and one with diphallus/
cloacal anomaly (Table 2). An additional 133 patients
were defined as having a 46,XY DSD of unknown origin
—broadly referring to those with varying degrees of
under-virilization phenotypes, such as micropenis, crypt-
orchidism, and non-isolated hypospadias for which the
underlying cause was unknown.
We also have DNA samples from 48 patients with
46,XX DSD (including 12 with family members). This
cohort includes 26 patients with a disorder of gonadal
(ovarian) development, including seven with 46,XX OT
DSD, 16 with testicular (T) DSD, and three with gonadal
dysgenesis. Nine individuals with 46,XX Mayer-
Rokitansky-Küster-Hauser syndrome (MRKH) and one
with dysplastic ovaries were also included. In addition,
we have DNA from ten patients with 46,XX virilization
of unknown origin (Table 2). Finally, 11 patients (46,XY
and 46,XX) who have been referred with a DSD as part
of a wider spectrum of anomalies, classified as syn-
dromic DSD, were included (Table 2). To our knowledge
around 30% of the cohort (both singletons and trios)
had undergone pre-screening prior to participating in
this study, such as single-gene Sanger sequencing (for
example AR, SRD5A2, HSD17B3, SRY, DHH, or WT1).
Our cohort of patients with DSD covers 12 countries
including Australia (83), New Zealand (7), Indonesia
(97), the Netherlands (38), Pakistan (25), Vietnam (35),
Cambodia (16), Austria (15), Belgium (6), Canada (2),
India (1), and Italy (2).
General characteristics of observed variants
Prior to filtering, 1,097,162 variants were observed in
the entire cohort of patient samples in diagnostic genes
and research candidates. Of these variants, 48% were ob-
served recurrently in the cohort, with the total set com-
prising only 57,320 unique variants; 12,257 variants were
novel (unseen in ESP6500, dbSNP, ExAC, or the 1000
Genomes Project) and 23% of novel variants were ob-
served recurrently in our samples and were interpreted
as either sequencing artifacts or common population
variants that are endemic to specific ethnicities in our co-
hort. These are largely removed by our variant filtering
process (see “Methods”). The majority (88%) of the pro-
tein changing variants observed in diagnostic genes were
characterized as missense. Protein changing INDELs were
dominated by inframe INDELs (14, 67%) followed by 1-bp
or 2-bp frameshift variants (11, 28%). Only two frameshift
INDELs larger than 2 bp were detected in the diagnostic
gene set. The predominance of inframe INDELs is consist-
ent with a high level of selection against significant disrup-
tion to these genes. However, the lack of observation of
larger INDELs may be partly due to insensitivity of the
analysis to longer INDELs.
Diagnostic DSD gene coverage and calling
Coverage of clinically diagnostic genes for DSD is of crit-
ical interest and indicates potential utility of the panel as
a diagnostic assay. In our evaluation data set, the design
covered 99.4% of the bases within the targeted regions of
these genes with at least one amplicon, while 97.2% of
bases were covered with two or more amplicons. We
evaluated total coverage of each DSD gene in 100 repre-
sentative patient samples (from three separate library
preparations). All genes except six had at least 90%
coverage at 20× or greater (Table 1). Those lower than
90% were SRY (a Y-chromosome linked gene which is
lower in this calculation because of the inclusion of both
females and males), AKR1C2, CDKN1C, CYP11B1,
FGF8, LHX3, and CYP21A2 (82, 61, 86, 88, 89, and 6%,
respectively) (Table 1). In some cases, large regions of
these genes were covered at less than 20× coverage depth.
For CYP21A2, low mappability of reads is caused by the
presence of a pseudogene with very high sequence hom-
ology. Pathogenic variants in CYP21A2 are thought to
underlie up to 90–95% of CAH [14]. However, given our
inability to confidently call variants in this gene, we have
excluded CAH patients from our cohort.
We observed a high level of variability in the number
of variants identified within each diagnostic gene. When
we considered the number of protein-changing variants
Table 2 Disorder of sex development patient cohort and variant summary (Continued)
(D) Unknown
46,XX DSD (origin unknown) 4 6 10 10 0 0 0 0
Total 46,XX DSD 12 36 48 39 9 8 0 1
Genetic diagnosis = 8 (17%)
Total all DSD 75 251 326 158 168 84 42 42
Patients have been categorized based on clinical notes provided, according to the recommended classification of DSD in the Chicago Consensus report [1]. The
number of singleton and patients with family members (duos or trios) are shown for each DSD. Given the difficulty of classifying some DSD patients, we have
included an “unknown” category for 46,XY undervirilized patients and 46,XX virilized patients with unknown cause. This table also lists the numbers of patients in
each DSD classification with a variant in a clinically relevant DSD gene. This is shown as a total number and broken down into variant classifications: pathogenic,
likely pathogenic, and variants of uncertain significance (VUS). Variants which are classified as pathogenic or likely pathogenic are considered to be a genetic diagnosis
and have been indicated for each phenotypic category. In cases where a patient had variants in multiple genes, the variant with the highest classification (pathogenic >
likely pathogenic > VUS) was taken into consideration for this chart. The exact variants in each patient can be found in Additional file 1: Table S1. Entries in bold are
subtotals and totals. MRKH Mayer-Rokitansky-Küster-Hauser syndrome
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per kilobase for each diagnostic gene we found that
some appear highly constrained and tolerate little pro-
tein changing variation, while others appear to tolerate
more variation (Fig. 2).
The targeted gene panel delivers a high genetic
diagnostic rate in 46,XY DSD
Sequencing was carried out on the total cohort (455
individuals). In total we found 28,785 observations in
diagnostic genes including recurrent variants; 2016 of
these were protein changing and rare (<1% minor allele
frequency in ESP6500, and 1000 Genomes Project),
meaning that, on average, each patient had around four
diagnostic gene variants. These were further filtered for
frequency in our database, inheritance, and quality/depth
(see “Methods”). Remaining variants were curated in ac-
cordance with previous publications using MPS analysis
of DSD cohorts [8, 10] (see “Methods”), which were
based on the American College of Medical Genetics and
Genomics (ACMG) guidelines [15]. Rare variants in a
clinically relevant DSD gene are reported here if our
curation processes classified them as pathogenic, likely
pathogenic, or variants of uncertain significance (VUS;
not predicted to be damaging or the affected gene has
not been previously reported with the described pheno-
type). Only variants classified as pathogenic or likely
pathogenic are considered a “genetic diagnosis” in ac-
cordance with guidelines.
In the 46,XY DSD cohort (278 patients) we found a
total of 159 individuals (57%) had a variant in a clinically
relevant DSD gene (Fig. 3a, Table 2). Of these, 76 had a
pathogenic variant (48%), 42 had a likely pathogenic
variant (26%), and 41 had a VUS (26%) (Fig. 3a). Thus,
our panel delivered a probable genetic diagnosis in 43%
of individuals affected by 46,XY DSD (the genetic diag-
nosis rate). The targeted gene panel proved less well
suited for those affected with 46,XX DSD. Only nine of
the 48 patients with 46,XX DSD had a DSD variant
(Fig. 3b, Table 2), eight of which showed the presence of
SRY material, suggesting a Y-translocation had occurred,
which explained the patient’s phenotype. One patient
carried a VUS. Our screen provided little insight into the
basis of the DSD in the 46,XX patients, who were con-
firmed SRY-negative; they were thus excluded from the
rest of the analyses. All curated variants are presented
for each patient in Additional file 1: Table S1.
A large and diverse DSD cohort enabled us to deter-
mine the proportion of genetic diagnoses across the
Fig. 2 Protein changing variants seen per kilobase sequenced for diagnostic genes. A lower number of variants per kilobase sequenced suggests
a higher intolerance to protein altering mutations for the gene, but may also be affected by lower ascertainment in regions that are difficult to
sequence. Diagnostic DSD genes are graphed alphabetically; differing colors are used only for clarity. A small number of genes are excluded because
they experienced artificially low variant counts due to technical reasons, including poor sequencing performance (CYP21A2, CDKN1C, LHX3), omission
from sequencing in some samples (CYB5A), or difficulties in annotating variants accurately (SRD5A2)
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various subgroups of 46,XY DSD patients (Table 2). Of
the 278 patients with a 46,XY DSD, we were able to de-
fine a genetic diagnosis in 40% of those with a disorder
of gonadal (testicular) development, 60% of those with a
disorder of androgen synthesis and action, 32% of those
classified as “other”, and 43% of patients with an un-
known 46,XY DSD (Fig. 3c, Table 2). Although our
screen performs particularly well for patients with a
46,XY DSD caused by a hormonal abnormality, a large
proportion (16 of 23 variants, 70%) of the identified vari-
ants had previously been reported in DSD. While the
genetic diagnosis rate was lower in patients with a dis-
order of gonadal (testicular) development, only 33% of
these variants (6 of 18 variants) had been previously de-
scribed in DSD. This is the first time a large cohort of
individuals affected with 46,XY DSD has been classified
into distinct subsets to provide insight into the genetic
etiology. This represents a dramatic improvement over
current methods.
Patients in our cohort have been recruited from 12 coun-
tries. To investigate whether our panel is informative for
different global regions, we grouped patients into Asia,
Australia/NZ, or Europe. Each region showed a similar pro-
portion of patients with a DSD gene variant; however, the
diagnostic rate varied between regions from 33% (58 of 174
patients from Asia) to 45% for Australia/NZ (41 of 90 pa-
tients) (Additional file 2: Figure S1). This likely reflects in-
clusion of a larger number of patients with hypospadias
from Asia, a DSD category in which the genomic basis is
poorly understood (and in which environmental factors
may play a role; reviewed in [16]). Nevertheless, our panel




Fig. 3 Genetic diagnosis of the DSD cohort. a Proportion of 46,XY DSD patients with a curated variant in a known DSD gene. In 46,XY DSD patients
(278 patients), a DSD variant was identified in 57% (159 patients) of the study cohort. This was made up of 76 pathogenic variants and
42 likely pathogenic variants, resulting in a diagnostic rate of 43%. A total of 41 VUS were also found. b In the 46,XX DSD patient cohort
(48), only 19% (9) were found to have a variant in a DSD gene, most of which were SRY translocations (8). This resulted in a diagnostic
rate of 17%. c Distribution of curated variants in DSD genes among the 46,XY DSD phenotypic categories. Variants in a diagnostic DSD
gene found to be pathogenic or likely pathogenic are considered to be a genetic diagnosis. The diagnostic outcome for each of the phenotypic
categories is indicated. Disorders of gonadal (testicular) development patients had a total of 21 out of 52 patients with a pathogenic or likely
pathogenic DSD variant (40%) and only two patients with a VUS (4%). Of the patients with a suspected disorder of androgen synthesis and
action, 22 patients of 37 had a diagnostic variant (60%) and four had a VUS (10%). Of patients in the 46,XY other category (including hypospadias), just
18 out of 56 had a diagnostic variant (32%), with 11 patients having a VUS (19%). Finally, in the broad category 46,XY DSD unknown, which includes
133 patients, 57 had a pathogenic or likely pathogenic (43%) variant, while 24 patients had a VUS (18%). In cases where a patient had variants in
multiple genes, the variant with the highest classification (pathogenic > likely pathogenic > VUS) was taken into consideration for this chart
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Variants identified in 28 diagnostic genes causative for
46,XY DSD
In our 46,XY DSD cohort, a total of 187 rare changes
were identified in clinically relevant DSD genes. Of
these, 22 occurred recurrently within our cohort. There-
fore, in total we identified 151 unique variants in 28
known DSD genes (Table 1, Fig. 4). More than half of
these unique variants (62%) had not been previously
reported in association with a disorder (in ClinVar, the
Human Gene Mutation Database (HMGD), Online
Mendelian Inheritance in Man (OMIM), or published in
PubMed), including 23 null and 70 missense changes
(Additional file 1: Table S1, Fig. 4).
Variants in the AR gene were the most common
(Fig. 4) with 26 unique variants curated. The majority of
these were classified as pathogenic (23 variants, 86%) as
Fig. 4 Reportable DSD variants identified in patients with 46,XY DSD. Variants were identified in 28 of a total of 64 diagnostic DSD genes. The
number of previously reported (as disease causing) and unreported changes found in each diagnostic DSD gene as well as the type of change
identified (missense or null variants) are shown (all variants can be found in Additional file 1: Table S1). The total number of variants is shown for
each gene. The clinical relevance of each variant was checked in ClinVar, HMGD, and OMIM databases and for prior publication in PubMed
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they were null mutations (eight variants) or had been
previously reported in association with a DSD phenotype
(20 variants) (Fig. 4; Additional file 1: Table S1). AR has
several highly repetitive tracts in exon 1 (GGN and CAG
tracts). Reductions or expansions of these tracts have
been suggested to contribute to numerous conditions,
including hypospadias [17–19] and undervirilization
[20]. We often observed patients with changes in these
genomic regions compared to the reference sequence, al-
though in many cases a proper validation of the repeat
number was not possible due to sequencing technology.
Thus, while we have identified these variants in patients,
we have labeled them as VUS-3.
NR5A1 and SRD5A2 had the second and third highest
number of variants called (16 and 13, respectively). Des-
pite the preponderance of NR5A1 publications associ-
ated with DSD, the majority of the variants we found in
NR5A1 had not been previously described (81%), includ-
ing seven null and six missense variants (Fig. 4). Con-
versely, the majority of variants identified in SRD5A2
(77%) were previously reported and a large proportion of
them occurred recurrently within our cohort (Fig. 4;
Additional file 1: Table S1).
Of interest, we identified eight unique variants in
DHH, all previously unreported. These were all classified
as damaging missense mutations with unknown inherit-
ance, three were heterozygous, two were detected as
homozygous, and two patients had two variants,poten-
tially as compound heterozygotes. A striking number of
variants were identified in ZFPM2 (11 variants in ten pa-
tients) and MAP3K1 (six variants in 11 patients). Both
of these genes have only been described in a limited
number of DSD cases [21, 22]. Three ZFPM2 variants
found in our study had been previously reported as
pathogenic variants in congenital heart disease [23], al-
though they have not been reported to be associated
with genital anomalies. In the case of MAP3K1, the ma-
jority of variants were unreported; however, three of
these variants were observed in more than one patient
with 46,XY DSD (Fig. 4; Additional file 1: Table S1).
Identifying oligogenic variants
Interestingly, a total of 13 46,XY DSD patients had
more than one curated variant in a diagnostic DSD gene.
Eight of these patients were classified as 46,XY DSD origin
unknown and five had hypospadias (Additional file 1:
Table S1, see patient IDs marked with as asterisk). Of the
eight patients with 46,XY DSD origin unknown, five indi-
viduals had a known variant in AR in combination with
another DSD gene variant; in two patients this was a
pathogenic variant in an additional DASA gene (SRD5A2
and HSD17B3) and in the other three it was a variant in a
testis development gene. Three individuals had a patho-
genic variant in a testis development gene (MAP3K1,
ZFPM2, and NR5A1) in combination with a less damaging
DSD gene variant (Additional file 1: Table S1).
Of the five patients with hypospadias, three were found
to have a likely pathogenic variant in a testis development
gene (MAP3K1 and ZFPM2) in combination with a VUS
in an additional DSD gene, while one patient had two
pathogenic variants, one in a DASA gene (HSD3B2) and
the other in a congenital hypogonadotropic hypogonadism
(CHH) gene (GNRHR). In most cases with oligogenic
inheritance, at least two of the genes were predicted to be
pathogenic and/or contribute to the phenotype.
Similar diagnostic rate in patients sequenced as singletons
or trios
We have sequenced 215 patients with 46,XY DSD as sin-
gletons and 63 patients as part of a trio/duo or with a
sibling. In singleton patients 128 of 215 (60%) had a vari-
ant in a diagnostic DSD gene, and for trios 31 out of 63
(43%) had a DSD variant (Fig. 5a, b). However, a likely
genetic diagnosis (individuals carrying a pathogenic or
likely pathogenic DSD variant) was found in 41% (26 of
63) of patients sequenced as a trio and 43% (92 of 216)
of patients sequenced as a singleton (Fig. 5a). A higher
proportion of singleton patients had a VUS (36 of 215,
17%) compared to trios (5 of 63, 8%). This may reflect
our inability to determine variant inheritance in single-
tons that would have led to discounting rare familial
changes. Overall, the similar genetic diagnostic rate
suggests that targeted sequencing of family members
alongside patients is not essential to reach an acceptable
genetic diagnosis in many cases of DSD.
Familial cases of DSD
We had seven familial cases of DSD in our cohort. Three
of these had a variant in a DSD gene: patients 238 and
239 are twins with hypospadias, both of whom had a
WDR11 VUS; patients 112 and 223 (father and son, both
with hypospadias) had a novel NR5A1 frameshift muta-
tion; patients 33 and 34 were 46,XY DSD patients with a
reported pathogenic variant in SRD5A2 (Additional file 1:
Table S1). In the other four familial cases no DSD genetic
variant was found with the current analysis.
Discrepancy between phenotype/genotype and genetic
clues for DSD of unknown origin
Due to the difficulty of diagnosing DSD patients, it is
often challenging to apply an appropriate DSD classifica-
tion to the presenting phenotype. In some cases our mo-
lecular diagnosis was at odds with the original clinical
DSD classification and allowed us to suggest a reclassifi-
cation, which could potentially inform clinical manage-
ment. For example, patient 42 was initially described
clinically as having partial androgen insensitivity, but
was found to have a heterozygous DHH variant. As our
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molecular diagnosis differed from the original clinical clas-
sification, we classified this variant as VUS-2 (predicted
pathogenic but does not fit phenotype; Additional file 1:
Table S1); therefore, further investigation is warranted.
In cases with limited phenotypic descriptors, genetic
analysis pointed to a more concise DSD classification.
This was performed on two groups of individuals, those
with 46,XY DSD unknown origin (undervirilization cat-
egory) and those with “isolated hypospadias”. The first
group (133 patients) consisted of the following: limited
clinical information, noted to have ambiguous genitalia,
undervirilization phenotypes including hypospadias,
bifid scrotum, micropenis, cryptorchidism, often with no
further description of either internal structures or hormo-
nal levels. When we reassessed this group by the type of
DSD variant identified, a significant proportion had vari-
ants in genes known to cause disorders of androgen
synthesis and action (36 patients, 27%) or disorders of go-
nadal (testis) development (25 patients, 19%) (Fig. 5c),
highlighting the potential genetic basis of their phenotype.
Our cohort also included 46 patients with 46,XY DSD
who were defined as having isolated hypospadias. Again,
this group of individuals were often referred with limited
clinical information. While ten of these patients (22%) did
have a variant in a gene known to cause isolated hypospa-
dias, six of the 46 patients (13%) had a variant in an an-
drogen synthesis or action gene and seven (15%) had a
variant in a gonadal (testis) development gene (Fig. 5c).
Relevance of CHH variants in 46,XY DSD
One interesting observation limited to both 46,XY origin
unknown and isolated hypospadias groups was that 9% of
patients carried a variant in a known CHH/Kallmann syn-
drome gene (a total of 16 patients; Fig. 5b, c. In general,
variants in CHH genes were rarely detected in patients
outside these groups (two other patients in total). Variants
were found in seven CHH genes (CHD7, KAL1, WDR11,
PROK2, PROKR2, FGF8, and FGFR1; Additional file 1:
Table S1). Five variants have been previously reported as
pathogenic in CHH, with a number of these showing
decreased activity in functional studies (e.g., FGF8
p.P26L, PROKR2 p.S188L and p.L173R) [24–26]. Of
the previously unreported variants, 18 were predicted
to be pathogenic by the in silico models used but were
classified as VUS-2 as the spectrum of phenotypes seen
in these patients does not correlate with a usually less
severe CHH phenotype. It is interesting to speculate
that these variants in the CHH genes may be contribut-
ing to 46,XY DSD phenotypes.
Discussion
DSD are a major pediatric concern, estimated to occur
in 1.7% of all live births [27]. Providing a molecular diag-
nosis for these patients is often difficult given the large
heterogeneity of clinical presentations included in this
group of disorders. A previous study has stated that a
clinical genetic diagnosis is only made in 13% of all DSD
patients in a hospital setting [7]. In particular, 46,XY
DSD are not well diagnosed at the molecular level. How-
ever, MPS is now fast becoming a standard assay for
molecular diagnosis of rare Mendelian disorders and has
been successfully used on small cohorts of DSD patients
[7, 8, 10]; in particular, a research study of 40 cases using
WES provided a likely genetic diagnosis in 35% [8]. We
present a MPS targeted DSD gene panel on one of the
a b
c d
Fig. 5 Analysis of the 46,XY DSD cohort: singletons versus trios and
patients with a DSD of unknown origin. a, b Singleton or trio analysis
of patients with 46,XY DSD. Individuals with 46,XY DSD were either
analyzed as a singletons (215 patients) or b trios/duos. The proportion
of patients with a DSD variant was higher for singletons than for trios:
68% (128 patients) versus 50% (31 patients). Singletons and trios had a
similar genetic diagnostic rate (pathogenic or likely pathogenic variant)
at 43 and 41%, respectively. A higher proportion of singletons had
a DSD variant classified as VUS (17% of all variants in singleton)
compared to trios (8% in trio analyses). c, d Gene variants reveal
biological basis of 46,XY DSD. Only limited clinical information was
often available for 133 origin unknown patients (c) and 46 hypospadias
patients (d). Based on their curated DSD variants, these patients have
been assessed on the categories of DSD gene function. In cases where
a patient had variants in multiple genes, the variant with the highest
classification (pathogenic > likely pathogenic > VUS) was taken into
consideration. Variants annotated VUS were also included in this analysis
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largest collections of 46,XY DSD reported to date (278 pa-
tients). Our data provide an improved genetic diagnostic
rate of 43% for these individuals. Targeted panel sequen-
cing offers many advantages over WES or WGS. It is an
economically viable option as reagent costs (AUD$300 for
our panel) and curation times are reduced and the
chances of incidental findings are negligible. Given that
WES sequencing is not currently funded by government
or private health care providers in Australia and other
jurisdictions, we propose our targeted DSD gene panel
should be considered as a first tier test in the clinical diag-
nosis and management of 46,XY DSD patients.
MPS evaluation
The capacity of a targeted gene panel as a diagnostic
tool is underpinned by its performance in diagnostic
gene sequencing. For the 64 diagnostic DSD genes we
observe almost complete coverage by our targeted gene
panel, with 99.4% of bases covered by at least one ampli-
con, and 97.2% of bases covered by at least two ampli-
cons. Despite the coverage by amplicons, we observed
significant regions over some diagnostic genes that were
covered by reads at less than acceptable levels for diag-
nostic use. In the case of CYP21A2 this was attributable
to the presence of a pseudogene having high homology
with the target gene. Such genes are extremely difficult
to interrogate with any technology in which short reads
are used due to the inability to uniquely map reads to
these locations. As such, the failure is not specific to the
HaloPlex technology we used for our targeted gene
panel, but relates to current MPS technology in general.
Other shortcomings were attributable to the distinctive
characteristics of the HaloPlex assay. For example, the
propensity for individual amplicons to sporadically fail
to produce reads requires that care be taken during the
targeted capture design to ensure important regions are
covered by multiple amplicons.
Overall, the effective targeting efficiency of our tar-
geted gene panel was comparable to that of other sys-
tems for targeted enrichment, with between 60 and 70%
of base reads generated from the targeted regions. Despite
some of the drawbacks associated with all current MPS
technologies, our analysis has shown that a targeted panel
can form a powerful diagnostic tool.
A large international cohort of patients with DSD
For this study, we compiled DNA from 326 patients and
129 family member participants, making this the largest
reported cohort of patients with DSD. We have shown
that our MPS targeted DSD gene panel is useful for the
identification of diagnostic variants in a wide range of
46,XY DSD, and a likely genetic diagnosis was achieved
in 43% of cases. It is interesting to note that prior to
their inclusion in our study, a large proportion (at least
30% to our knowledge) of the patients had undergone
genetic pre-screening (such as single-gene Sanger se-
quencing or microarrays), which ultimately affects our
overall diagnostic rate. This suggests that if applied as a
first-tier diagnostic test, we could expect our panel to
provide an even greater diagnostic outcome. Our results
support previous conclusions reached by others [7, 8, 10]
indicating that diagnosis of 46,XY DSD can be signifi-
cantly enhanced through use of MPS technologies, albeit
on a much larger scale.
Our highest diagnostic rate of 60% (22 of 37 individuals)
is for patients who have disorders of androgen synthesis
and action. A large proportion of these patients had vari-
ants previously described in DSD (17 of 22, 77%), primar-
ily variants in AR and SRD5A2. The publically available
AR database has a total of 546 unique entries (this in-
cludes recurrent variants associated with different pheno-
types), with 339 of them associated with DSD [28]. Of the
26 unique AR variants found in our 46,XY DSD cohort,
only six were previously unreported (four null mutations
and two missense), suggesting the vast majority of DSD-
causing AR variants have been defined.
Large-scale MPS sequencing has not been previously
reported for 46,XX DSD; therefore, we analyzed 48 pa-
tients with various forms of 46,XX DSD to determine
how a targeted gene panel would perform. We found
that gene panel testing is not informative for 46,XX
DSD in its current format. The majority of 46,XX DSD
patients included in our study were reported to have had
a prior test to examine gain of SRY. We independently
identified eight patients carrying SRY (indicative of
translocation) from our 46,XX DSD cohort. Transloca-
tion of SRY accounts for approximately 80% of individ-
uals with 46,XX testicular DSD [29]. The majority of
other reports describing the molecular basis for disor-
ders of ovarian development are copy number variants
(CNVs) in a number of testis-promoting or ovary-
promoting genes (for example, SOX9 [30–33], FGF9
[34], RSPO1 [35, 36], WNT4 [37, 38]; reviewed in [20]).
A recent study showed the contribution of small exon
level deletions in Mendelian disease has been underesti-
mated [21], highlighting the need for similar analyses in
46,XX DSD. Further work to assess the ability of our
targeted gene panel in detecting CNVs is underway.
Identification of variants: prevalence in disorders of
gonadal (testicular) development
This study has allowed us to identify a total of 76 patho-
genic, 42 likely pathogenic variants, and 41 VUS in
known DSD genes, more than half of which were previ-
ously unreported. This substantially expands our current
knowledge of diagnostic DSD variants. In a study on
DSD patients using WES, Baxter et al. [8] identified a
number of patients with variants in MAP3K1, a gene
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previously associated with 46,XY CGD [22]. Similarly,
we found 11 patients with heterozygous variants in
MAP3K1 representing six separate variants. Interest-
ingly, a variant we detected in two patients with 46,XY
CGD (p.L189R) had been previously reported in individ-
uals with a similar phenotype [22].
We also observed two MAP3K1 variants (p.M312L
and p.A1443V) that recurred in multiple patients who
presented with a diverse range of phenotypes (including
CGD, PGD, hypospadias, and undervirilization). This
suggests variants in this gene may be associated with a
greater phenotypic variability than had been previously
thought, although population specific polymorphisms
may be involved with the less severe phenotypes. While
a high level of variability between the number of variants
in each diagnostic gene was observed, MAP3K1 showed
intolerance to protein changing variation compared to
other genes, both in our data and also on ExAC (with a
missense Z-score of 1.53 and a probability of LOF in-
tolerance of 1). Given this, and previous reports using
exome sequencing in a smaller cohort [8], we can confi-
dently infer 10% prevalence of MAP3K1 variants
amongst 46,XY disorders of gonadal (testicular) develop-
ment classification (5 of 52 patients); however, this could
be up to 18% if the MAP3K1 phenotypic spectrum is ex-
panded. Further functional analysis will be required to
fully test these previously unreported variants.
A number of studies have identified DHH variants in
individuals presenting with a range of gonadal dysgenesis
(46,XY partial GD to complete GD), with or without
polyneuropathy [39–42]. The majority of these variants
were homozygous, with only one report of a heterozy-
gous single base pair deletion causing 46,XY PGD [40].
We identified seven patients with eight previously unde-
scribed DHH missense variants (none were reported to
have polyneuropathy). Homozygous or potentially com-
pound heterozygous DHH variants were identified in
four patients presenting with 46,XY DSD female pheno-
type, while the three individuals with heterozygous DHH
variants had diverse phenotypes, including DASA, DSD
origin unknown, and hypospadias. The clinical signifi-
cance of heterozygous DHH variants is still unclear;
however, variants in this gene can present as apparent
DASA due to an impairment of Sertoli cell–Leydig cell
interaction during gonad development [39]. Identifying a
genetic diagnosis in DHH can impact clinical manage-
ment due to the increased risk of gonadal malignancy in
such patients [39, 40].
In humans, mutations in ZFPM2 have commonly been
shown to be associated with congenital heart disease
[23] but only recently have heterozygous and homozy-
gous missense variants been detected in individuals with
isolated 46,XY PGD and CGD [21]. We identified nine
ZFPM2 missense and one frameshift mutation in six
patients with 46,XY disorders of testicular development
(52 patients), providing a genetic outcome for 12% of
these patients.
We also observed ZFPM2 variants in three individuals
with hypospadias and in some instances this was in con-
junction with another DSD gene variant that had not pre-
viously been reported. In the case of MAP3K1, DHH, and
ZFPM2 it is difficult to distinguish whether variants identi-
fied in patients categorized as isolated hypospadias expand
the known mutation spectrum of these genes or whether
these patients have underlying gonadal dysgenesis.
A role for oligogenetic inheritance in DSD
A recent report suggested that the expanded DSD
phenotypic spectrum associated with NR5A1 mutations
was attributed to oligogenic inheritance in other testis
development genes such as MAP3K1 [43]. Similarly we
found evidence of this accumulative effect within our co-
hort of patients with severe hypospadias. In three of
these patients we found oligogenetic inheritance of a
variant in a testis development gene (MAP3K1 and
ZFPM2) in combination with a VUS (often in a CHH
gene). Another patient (251*), also with severe hypospa-
dias, was found to have two pathogenic variants, one in
HSD3B2 (a gene implicated in proximal hypospadias)
[44] and the other in a known CHH gene, GNRHR. Fi-
nally, in patients with 46,XY DSD of unknown origin we
found five with an AR mutation in combination with an
additional variant in either androgen action or gonadal
development. This suggests that like NR5A1, AR may
show oligogenic involvement in DSD.
CHH leads to a reduction in gonadotrophin release
from the pituitary and can present as an inability to
enter puberty or even as mild undervirilization at birth
in 46,XY males [45]. This has been reported to be asso-
ciated with phenotypes such as cryptorchidism and
micropenis, but is typically thought not to cause isolated
hypospadias or more severe phenotypes such as ambigu-
ous genitalia. We found a significant proportion of the
patients with 46,XY undervirilization or hypospadias had
predicted pathogenic or previously reported variants in
genes that are known to cause CHH. This has also been
seen in WES sequencing of DSD patients [8], raising the
intriguing possibility that mutations in these genes may
contribute to a broader base of DSD phenotypes than
previously thought.
Sequencing singletons and trios delivers a similar diagnostic
rate
Where MPS is concerned, trios are often encouraged as
the gold standard, to allow better variant filtering and
curation. Although the total number of individuals se-
quenced in our study as singletons versus trios/duos was
substantially different (215 versus 63), we found that the
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proportion of patients with a probable genetic diagnosis
was similar between these groups. We observed a higher
number of variants curated and deemed VUS in the
singletons, variants which may not have stood up to
scrutiny if the mode of inheritance was known (where
familial variants are removed). Screening patients with
DSD as singletons provides a cost-effective clinical gen-
etic diagnosis that is comparable to trio analyses, al-
though trio analysis can reduce overall curation time.
Nevertheless, in a gene discovery setting, trio analysis
will still be highly valuable as it eliminates rare familial
variants, confirms modes of inheritance, and detects de
novo events.
Genetic screening provides clues for biological basis of
DSD and clinical management
We found our panel to be highly informative for patients
affected by DSD with an unknown biological basis.
Given that this kind of sequencing is relatively inexpen-
sive and quick and has a high genetic diagnostic rate, it
has potential as a first-tier clinical test to help inform
clinical management. A molecular diagnosis can provide
clues as to the biological basis of DSD and may direct
clinicians towards a specific clinical test. This could be
particularly useful in situations or countries in which
clinical tests such as histopathological examination, hor-
monal profiling, and advanced imaging are costly or not
routinely performed. We have shown that our gene
panel will assist with DSD classification in a situation
where an in-depth clinical presentation is not available.
The caveat to this is that the mutation spectrum of a
number of genes encompasses multiple clinical presenta-
tions. For instance, the spectrum of NR5A1 mutations
presented in our 46,XY cohort as CGD (two patients),
PGD (four patients), hypospadias (one patient) and
DASA (one patient); additionally, it has also been shown
to include spermatogenic failure [46]. This needs to be
taken into consideration, as a patient with a variant in
NR5A1 cannot be strictly classified as having a disorder
of testis development. However, genetic etiology is crucial
for informing clinical management and provides insights
into the diverse heterogeneous nature of DSD.
In clinical genomics, systematic classification guide-
lines are constantly evolving as evidence-based tools, re-
sources, and databases become available. We followed
the same process employed by previous genomic studies
of DSD patients [8, 10], based on the ACMG guidelines
for curation of clinical variants. Nevertheless, several
limitations of our study hindered curation—the lack of
parental/familial samples for many patients and, in some
cases, limited clinical phenotyping. In addition, as we
did not sequence unaffected control samples from each
ethnic group we assayed, we relied heavily on online da-
tabases like ExAC for population allele frequencies.
These may not always accurately reflect small ethnic mi-
norities. Future adoption of our panel as an accredited
clinical diagnostic test will resolve these issues for pro-
spective cases as a more stringent variant classification
would be used.
Although a success on many levels, our genetic panel
did not provide answers for 39 patients with 46,XX DSD
and 52 patients with 46,XY DSD where no diagnostic
variant was detected. Like many sequencing technolo-
gies, there are regions in our panel that have low cover-
age. As we do not use alternative methods to fill these
gaps, it is possible that we might miss diagnostic variants
that fall within these regions. One limitation of targeted
gene sequencing is that detection of CNVs is signifi-
cantly more challenging than single nucleotide variants
or INDELs. While a range of CNV detection methods
have been developed to work with targeted sequencing
data, specialized bioinformatic expertise is required to
obtain accurate results. Furthermore, standard methods
are generally not optimized well for use with the HaloPlex
technology. CNVs are known to contribute to DSD, and
our current inability to detect these in our targeted gene
panel means that we may be missing diagnostic changes
in DSD patients. We are currently working to create a bio-
informatic pipeline designed to use these data to assay for
CNVs, which will be a useful additional tool in the future.
While this study has focused on diagnostic DSD genes,
our targeted panel also includes 967 candidate genes
identified from animal model studies, implicated genetic
pathways, and gonad RNA-seq experiments. Currently,
our research group is pursuing several novel candidate
genes identified from these data, although these studies
are ongoing and beyond the scope of this article. Further
analysis of these genes (as well as WES or WGS sequen-
cing and microarrays on select patients) promises to re-
veal novel candidate genes that may contribute to the
development (and disease) of the reproductive system in
humans. Future detailed analysis of these genes and their
function will further improve genetic diagnosis and clinical
management of DSD.
Conclusions
Our targeted DSD gene panel is an effective means of
providing a genetic diagnosis for patients with 46,XY
DSD (43% of cases). Employing this in a large, diverse
cohort of patients with DSD has provided us with a bet-
ter understanding of the underlying genetic etiology of
this condition. In particular, we have expanded the range
of phenotypes associated with several DSD genes. Given
the rapid turn-around time and reduced cost compared
to WES or WGS, we believe that this targeted gene
panel could be used as a first tier clinical diagnostic test
for 46,XY DSD to assist in optimizing clinical manage-
ment for these patients.
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Methods
Ethics statement
This project (Molecular genetics of sex determination
and gonad development, HREC 22073) has been ap-
proved by the Royal Children’s Hospital (Melbourne,
Australia) ethics committee. Patients and family mem-
bers were enrolled after signing informed consent (and
in the case of minors, parental consent was also ob-
tained). For patients recruited in countries other than
Australia, consent was also obtained using local ethics
and consent and DNA transferred through a memoran-
dum of understanding between the Murdoch Childrens
Research Institute (MCRI) and the corresponding insti-
tute/hospital. This study was conducted in compliance
with the Helsinki Declaration.
Patient clinical data
Clinical notes were collected for each patient during their
standard clinical care by trained clinicians, and these data
were transferred to us under the informed consent (HREC
22073). This often included a description of their external
genitalia, internal reproductive organs, hormonal profile,
and additional notes of interest (i.e., additional anomalies
or family history). All of the patients had undergone
karyotyping. Many patients had previous clinical microar-
rays and or SRY screening. Some had had single-gene
sequencing (i.e., AR). Only patients that were negative for
these tests were included in the cohort discussed here.
De-identified DNA from each patient was stored in a
secure DNA storage facility.
DNA extraction
Genomic DNA extraction from EDTA-blood samples was
performed in an independent laboratory such as Victorian
Clinical Genetics Service (VCGS), or at local hospitals.
DNA quality was assessed using an Agilent gDNA Screen-
Tape run on 2200 TapeStation (Agilent Technologies Inc.)
and concentration was measured in our laboratory on a
Qubit 3.0 Flurometer using the broad range DNA quanti-
fication kit (ThermoFisher scientific).
Targeted panel design
The targeted panel uses the Agilent HaloPlex method
for sample preparation and was designed using the
Agilent SureDesign software (https://earray.chem.agilent.
com/suredesign/). The gene panel currently includes a
total of 1031 genes, microRNAs, and potential regula-
tory regions. These targeted regions comprise 64 known
diagnostic genes for DSD (Table 1), potential DSD can-
didate genes from human and animal studies, as well as
whole pathways with one or more genes being associated
with DSD (capture size 2.5 Mb).
Targeted gene panel library preparation
Library preparation was carried out according to the
manufacturer’s instructions, with the exception that half
reactions were performed. Briefly, genomic DNA
(125 ng gDNA) was digested with 16 different restriction
enzymes at 37 °C for 30 min to create a library of gDNA
restriction fragments. Both ends of the targeted fragments
were then selectively hybridized to biotinylated probes
from the HaloPlex DSD panel (Agilent Technologies Inc.),
which resulted in direct fragment circularization. During
the 16-h hybridization process, HaloPlex Illumina Bar-
codes were incorporated into the targeted fragments. Cir-
cularized target DNA–HaloPlex probe hybrids containing
biotin were subsequently captured by HaloPlex magnetic
beads on the Agencourt SPRIPlate Super magnet mag-
netic plate. DNA ligase was added to close the nicks in the
hybrids and freshly prepared NaOH was used to elute the
captured target libraries.
The target libraries were then amplified and purified
using AMPure XP beads. Amplicons ranging from 150
to 550 bp were finally quantified using an Agilent D1000
DNA ScreenTape on the 2200 TapeStation to validate
the enrichment of the libraries.
MPS was carried out according to the manufacturer’s
instructions at the Translational Genomics Unit at the
Murdoch Childrens Research Institute /VCGS, using ei-
ther the Illumina MiSeq, NextSeq500, or HiSeq4000 or
at the Centre for Translational Pathology, The University
of Melbourne using an Illumina HiSeq2500. For the case
of MiSeq samples, paired-end 2 × 150-bp reads were
used, while the HiSeq 2500 produced 2 × 150-bp reads.
Bioinformatic analysis
The sequencing data were analyzed using Cpipe, an ex-
ome analysis pipeline designed at MCRI [47]. Cpipe was
customized to improve performance on HaloPlex data in
several ways. The reads were first trimmed using an in-
house trimming method specialized for HaloPlex reads.
The custom trimming method detects contamination by
matching the expected sequence that will be observed
when adapter sequence appears adjacent to the known
amplicon boundaries in the sequencing data. The trimmed
reads were aligned using the BWA mem [48] alignment
algorithm, followed by base quality score recalibration and
local realignment around INDELs using the Genome Ana-
lysis Toolkit (GATK) [49]. Notably, deduplication of reads
was not applied, consistent with Agilent recommendations
for processing HaloPlex data. This requirement stems
from the properties of HaloPlex data in which reads
appear in tall towers sharing identical start and end
positions. Such reads are falsely considered to be PCR
duplicates by deduplication software, and thus dedu-
plication causes a severe and unnecessary loss of read
coverage depth. Variants were called using the GATK
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UnifiedGenotyper and annotated using a combination of
SnpEFF [50] and Annovar [51] to predict protein changes,
population frequencies and add other functionally inform-
ative data about each variant. The customizations to Cpipe
(Cpipe version 2.1) and specialized trimming software are
available at https://github.com/ssadedin/halo_dsd and in
Zenodo (64133851; https://zenodo.org/badge/latestdoi/
64133851).
Four in silico models, SIFT [52], Polyphen2 [53], LRT
[54], and Mutation Taster [55], were used as well as
GERP++ in some cases [56]. Manual mapping of the gen-
omic changes and submission to the in silico tool was per-
formed for variants identified in SRD5A2 as the transcript
was retired (transcript reference NM_000348.3).
Variant filtering and curation
Frequency Variant files were filtered to include only
rare (1000 Genomes Project ≤0.01 and ESP5,400 or
ESP6,500 ≤0.01), functional variants (different ESP data-
bases reflect updates during our analysis). As we did not
run control samples from each ethnic subgroup, the al-
lele frequency of population subgroups most reflecting
the ethnic background were checked on ExAC and vari-
ants discounted if they were common (>0.01). In addition
to public databases, the variant frequency within our co-
hort (as a total database call and a frequency per sequen-
cing run) was also tracked. This allows us to identify
variants that may be the result of amplification or sequen-
cing error (which are common in one sequencing run), or
that may be common in a subpopulation but not well rep-
resented on publically available databases (i.e., Indones-
ian). Thus, we also discounted variants found in greater
than 15 samples in the same run or in the total database.
Following this, only variants in known diagnostic DSD
genes (64) were considered.
Variant quality/depth Variants in known DSD genes
were evaluated for coverage depth and read quality and
also visually inspected using the Integrative Genomics
Viewer (http://www.broadinstitute.org/igv/). In some
cases of low coverage or depth, validation by Sanger
sequencing using the standard protocol for BigDye®
Terminator v3.1 Cycle Sequencing Kit (Life Technologies,
Carlsbad, CA, USA) was carried out at the Centre for
Translational Pathology, The University of Melbourne.
Inheritance If the inheritance mode did not fit with
the described phenotypic/genotypic spectrum, then
the variant was not considered for further curation.
For trios and families, different additional filters were
applied to distinguish between de novo, maternally or
paternally inherited, and compound heterozygous gen-
etic models.
Variant curation Variants previously reported to cause
disease in OMIM, ClinVar, HMGD, and PubMed
searches were hereafter called as “reported”. Each variant
was then classified according to the following curation
guidelines. Pathogenic variants are null mutations, such
as frameshifts, deletions, premature stop codons, and
splice site mutations, in genes where a loss of function is
a known disease mechanism and where the described
phenotype correlated with the patient’s. Alternative tran-
scripts and splice site variations were taken into account.
Missense variants previously found in a patient with a
similar clinical presentation were also considered patho-
genic variants. Likely pathogenic variants are novel
missense variants in known DSD genes that fit the
phenotype, had the correct inheritance pattern, and are
predicted to be damaging in greater than three of our
four in silico prediction tools. The remaining variants
were of unknown significance (VUS). These were further
separated into VUS-1 (within the disease spectrum/fit
clinical notes but predicted benign), VUS-2 (predicted
deleterious (in at least three of four in silico predictors)
yet not within the known spectrum of phenotypes), or
VUS-3 (if they fell within the region of CAG or GGN re-
peats in the AR receptor, regions of which the relevance
in DSD is as yet unclear).
Additional files
Additional file 1: Table S1. DSD gene variants. Each variant found in a
diagnostic gene (after the filtering and curation process) is shown. In
some cases where the gene is inherited in an autosomal recessive manner,
two variants are grouped together. Inheritance has been indicated where
familial samples were available: negative indicates negative for variant and
N/A sample not available. De novo events have only been noted where
both parental samples were available and found to be negative for the
change. Previously reported refers to a variant being described in either
ClinVar, HGMD, or a publication in a peer-reviewed journal via a PubMed
search. Variants were classified consistent with previous MPS publications
of DSD cohorts [8, 10] which were based on ACMG guidelines [15]. VUS
were called for three reasons: 1 = fits phenotype but predicted to be
benign; 2 = damaging but doesn’t fit phenotype; or 3 = variant in
the AR repetitive region. Patients marked with an asterisk were identified to
have two or more diagnostic gene variants. Null variants (frameshifts, splice
sites mutations, and premature stop codons) are shown in bold. Patients
have been classified based on clinical notes provided, according to
the recommended classification of DSD in the Chicago consensus report.
Classifications: CGD complete gonadal dysgenesis, DASA disorders of
androgen synthesis or action, DSD DSD of “unknown” origin; hypospadias,
LCH Leydig cell hypoplasia, OT ovotesticular DSD, PGD partial gonadal
dysgenesis, PMDS persistent Müllerian duct syndrome; syndromic, T testicular
DSD. Related affected individuals are indicated. File is in Excel spreadsheet
format. (XLSX 47 kb)
Additional file 2: Figure S1. DSD gene variants in different global
regions. DSD gene variants among the international cohort of 46,XY DSD
patients. For ease of analysis, countries were grouped together into
regions: Asia comprises Indonesia (97), Pakistan (25), Vietnam (35),
Cambodia (16), India (1), a total of 174 patients ; Europe comprises the
Netherlands (38), Austria (15), Belgium (6), and Italy (2), a total of 61
patients; and AUS & NZL comprises Australia (83) and New Zealand (7),
a total of 90 patients. All curated variants are shown; those which have
been curated and called pathogenic, likely pathogenic, and VUS. In the
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cohort from Asia, 35% of the patients were found to have a diagnostic
variant (pathogenic or likely pathogenic), while this was 44% for Europe
and 45% for AUS/NZL. Two patients from Canada were not included in
the diagram. (PPTX 158 kb)
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